AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.39
+1.62%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.34
From 52W high−28.62%
Volume390038.00
Market cap$352.10M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$4.34
From 52W high
−28.62%
Volume
390038.00
Market cap
$352.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
24.2
MomentumView details →
1D Return
+1.62%
YTD Return
+19.75%
SummaryUpdated Jun 1, 2026
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Boston, Massachusetts. The company went public in October 2020 and focuses on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea has transitioned from a multi-program antiviral company to primarily focusing on two key therapeutic areas: COVID-19 treatment and hepatitis C virus (HCV) treatment, after deprioritizing its dengue fever program in 2022 due to clinical development challenges.
Similar companies
Latest newsMore news →
Atea Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.68d agoAtea Pharmaceuticals reported that its Phase 3 C-BEYOND trial of BEM/RZR for hepatitis C met primary and secondary endpoints, supporting a potential best-in-class profile.68d agoAtea Pharmaceuticals announced that its Bemnifosbuvir/Ruzasvir met primary and secondary endpoints in the Phase 3 C-BEYOND North America trial for hepatitis C virus treatment.84d ago